SCHEMBL6078046

SCHEMBL6078046

O=C(O)c1cc(NS(=O)(=O)c2ccc3ccc(N4CCN(c5ccc6ccc(S(=O)(=O)Nc7ccc(O)c(C(=O)O)c7)cc6c5)C4=O)cc3c2)ccc1O

nearest known ligand 0.80

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.65
MEN1 O00255 5/20 0.65
KMT2A Q03164 5/20 0.65
PTPN5 P54829 1/20 0.51
CASP6 P55212 1/20 0.51
TSHR P16473 1/20 0.48
POLB P06746 3/20 0.48
KDM4E B2RXH2 2/20 0.48
HSD17B10 Q99714 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MAPT P10636 2/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
HTT P42858 1/20 0.45
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6428010 0.89 LMNA (0.54) ALDH1A1MEN1KMT2AL3MBTL1GAA
SCHEMBL6077882 0.80 ALDH1A1 (0.77) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL6079020 0.79 ALDH1A1 (0.76) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL6078042 0.78 ALDH1A1 (0.56) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL6079433 0.78 ALDH1A1 (0.71) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL7966502 0.74 ALDH1A1 (0.67) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL18175045 0.73 ALDH1A1 (0.73) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL11580250 0.72 ALDH1A1 (0.68) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL9997703 0.72 ALDH1A1 (0.67) ALDH1A1MEN1KMT2APTPN5CASP6
SCHEMBL16366458 0.71 ALDH1A1 (0.75) ALDH1A1MEN1KMT2APTPN5CASP6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP claimed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US claimed
JP-2003500381-A 2003-01-07 JP claimed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US claimed
EP-1181271-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS Telik, Inc. (US) 2002-02-27 EP claimed
WO-2000071506-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK, INC. (US) 2000-11-30 WO claimed
US-7071231-B2 Naphthalene ureas as glucose uptake enhancers TELIK, INC. (US) 2006-07-04 US disclosed
EP-1181271-B1 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2005-01-19 EP disclosed
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers SPEVAK WAYNE R (US) 2003-07-17 US disclosed
US-6458998-B1 NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS TELIK, INC. 2002-10-01 US disclosed
EP-1181271-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS Telik, Inc. (US) 2002-02-27 EP disclosed
WO-2000071506-A9 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK INC (US) 2001-09-20 WO disclosed
WO-2000071506-A2 NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS TELIK, INC. (US) 2000-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135063-A1 Novel naphthalene ureas as glucose uptake enhancers GPR119, SLC2A8, SLC2A1 ALDH1A1 3426/4885MEN1 3696/4885KMT2A 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.